This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
BioLegend
other brands :
Babco, Signet, Sternberger Monoclonals, Senetek, Covance
product type :
antibody
product name :
LEAF™ Purified anti-human CD210 (IL-10 R)
catalog :
308805
quantity :
50 μg
price :
120 USD
clonality :
monoclonal
host :
rat
conjugate :
nonconjugated
clone name :
3F9
reactivity :
human, Rhesus monkey
application :
neutralization, immunoprecipitation, flow cytometry
citations: 3
Reference |
---|
product information
Antigen :
CD210 (IL-10 R)
Apps. Abbrev. :
Flow Cytometry, Block, IP
Cat # :
308805
Clone :
3F9
Item :
LEAF™ Purified anti-human CD210 (IL-10 R)
Isotype :
Rat IgG2a, κ
Other Names :
IL-10 Receptor, IL-10R
Size :
50 μg
Price (USD) :
120 USD
Reactivity :
Human, African Green, Baboon, Cynomolgus, Rhesus
Clonality :
Monoclonal
Host :
Rat
Conjugate/Tag/Label :
LEAF
Immunogen :
shIL-10R
Application Notes :
Clone 3F9 recognizes the IL-10-binding epitope of IL-10R1. 8 Additional reported applications (for the relevant formats) include: immunoprecipitation 1 , in vitro blocking 1-3 of human IL-10 binding to IL-10R. For most successful immunofluorescent staining results, it may be important to maximize signal over background by using a relatively bright fluorochrome-antibody conjugate (Cat. No. 308804) or by using a high sensitivity, three-layer staining technique (e.g., including a biotinylated anti-rat IgG second step (Cat. No. 405402), followed by SAv-PE (Cat. No. 405204). The LEAF purified antibody (Endotoxin 0.1 EU/ug, Azide-Free, 0.2 um filtered) is recommended for functional assays (Cat. No. 308806). For highly sensitive assays, we recommend Ultra-LEAF purified antibody (Cat. No. 308810) with a lower endotoxin limit than standard LEAF purified antibodies (Endotoxin 0.01 EU/ug).
company information

BioLegend
9727 Pacific Heights Blvd.
San Diego, CA 92121
San Diego, CA 92121
customerserv@biolegend.com
https://www.biolegend.comheadquarters: USA
questions and comments